[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"female\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:female":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,46,98,133,155,177,204,235,258,287,318,345,377,401],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100640415","fluorocholine-petmr-in-breast-cancer-100640415",false,"NCT07587086","Fluorocholine PET\u002FMR in Breast Cancer","Use of Imaging Markers by Fluorocholine PET\u002FMR to Predict Molecular Subtypes and Clinical Outcomes of Breast Cancer: a Pilot Study","Inclusion Criteria:\n\n* Women aged 25-75 years old.\n* Women diagnosed as breast cancer by pathological diagnosis from core biopsy within 3 months and who will receive neoadjuvant chemotherapy (NAC) before surgery; or women with pathologically proven breast cancer within 3 months and who will receive operation (without pre-operative neoadjuvant chemotherapy).\n* Women whose ECOG between 0-2 points and life expectancy ≧ 3 months.\n\nExclusion Criteria:\n\n* Women who are unable to cooperate with the examinations\n* Women who are pregnant, lactating or are planning to be pregnant\n* Women with estimated GFR (eGFR) \\\u003C 60 ml\u002Fmin\u002F1.73m2 or acute renal failure within 3 months, past history of renal dialysis.\n* Past history of claustrophobia\n* Past history of anaphylactoid reactions to MRI contrast agents or PET tracer agents.\n* Women with cardiac pacemaker, aneurysmal clip, mechanical valve replacement, recently applied coronary artery stent (\\\u003C3 months).\n* Past history of breast cancer or other malignancy within 5 years.\n* Women who underwent chemotherapy within a year.\n* Women who are not suitable to join the study according to the assessment by investigators.","FEMALE","25 Years","75 Years",{"count":20,"type":21},195,"ESTIMATED","40 Weeks","OBSERVATIONAL","Objectives:\n\nOur study is conducted to use the pre-treatment FCH PET\u002FMR in breast cancer patients, to investigate whether the conventional PET\u002FMR imaging markers (SUVmax, MR spectroscopy-derived choline analysis, dynamic contrast-enhanced MRI, ADC analysis), and FCH\u002FMR radiomic features, deep learning (DL) analysis are associated with molecular subtypes, clinical outcomes, treatment response, survival, and which parameters are more accurate for prediction purposes.\n\nPrimary study purposes:\n\n-To investigate whether the pre-treatment FCH PET\u002FMR imaging parameters are associated with molecular subtypes of breast cancers, and to evaluate the diagnostic performance for prediction purpose.\n\nSecondary study purposes:\n\n\\- To investigate whether the pre-treatment FCH PET\u002FMR imaging parameters are associated with the factors related to clinical outcomes (histologic grade, prognosis) and to analyze which parameters are more accurate for prediction purposes.\n\nTest drug:\n\nName: 18F- Fluorocholine (18F-FCH) Dosage form: N-(\\[18F\\]fluoromethyl)-2-hydroxy-N,N-dimethylethan-1-aminium Strength: 3-5 MBq\u002Fkg per patient (5-6 mCi\u002FmL at time of injection (TOI)) Dosage and administration: Intravenous injection.\n\nSelection criteria:\n\n1. Women aged 25-75 years old.\n2. Women diagnosed as breast cancer by pathological diagnosis from core biopsy within 3 months and who will receive neoadjuvant chemotherapy (NAC) before surgery; or women with pathologically proven breast cancer within 3 months and who will receive operation (without pre-operative neoadjuvant chemotherapy).\n3. Women whose ECOG between 0-2 points and life expectancy ≧ 3 months.",[26,27],"Breast Neoplasms","Female",[29,30,31,32],"Breast Cancer","FCH(18F- Fluorocholine)","Radiomics","PET\u002FMRI","RECRUITING","2026-05-08",{"date":36,"type":37},"2026-05-14","ACTUAL",{"date":39,"type":37},"2022-06-14",{"date":41,"type":21},"2028-07-31",{"name":43,"class":44},"Taipei Veterans General Hospital, Taiwan","OTHER_GOV",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":78,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":45},"100572617","wild-blueberries-for-gut-brain-and-heart-health-in-adults-with-high-blood-pressure-100572617","NCT06735599","Wild Blueberries for Gut, Brain, and Heart Health in Adults With High Blood Pressure","Effects of Wild Blueberry Consumption on Gut, Brain, and Cardiovascular Health in Non-Hispanic Black and White Adults With High Blood Pressure","Inclusion Criteria:\n\n* Individuals 45-65 years of age\n* Diagnosis of elevated blood pressure or stage 1 hypertension (systolic blood pressure = 120-139 mmHg and\u002For diastolic blood pressure = 80-89 mmHg) for at least 6 months\n* BMI 25-35 kg\u002Fm2 via anthropometric measurements.\n* Ability to give consent\n\nExclusion Criteria:\n\n* Allergies to berries\n* Use of one hypertensive drug for less than three months\n* Use of more than one anti-hypertensive or statin drug, insulin, antibiotics, and anti-inflammatory drugs, active cancer, gastrointestinal, renal, cardiovascular, thyroid, and neurological disorders or severe head injury\n* Smoking\n* Alcohol consumption (\\>2 drinks\u002Fday)\n* Consuming antioxidant, probiotic, and prebiotic supplements\n* Pregnant or lactating\n* Participating in a weight loss program","ALL","45 Years","65 Years",{"count":57,"type":21},40,"INTERVENTIONAL",[60],"NA","The purpose of the study is to determine the effectiveness of wild blueberries on cardiovascular health, cognitive function, and gut microbiota composition in non-Hispanic Black and White adults with elevated blood pressure.",[63,64,65,27,66,67,68,69,70,71,72,73,74,75,76,77],"Hypertension (Without Type 2 Diabetes Mellitus)","High Blood Pressure","Male","Adult","Cognition","Endothelial Function (Reactive Hyperemia)","Oxidative Stress","Diet","Overweight","Body Composition Measurement","Gut Microbiome","Arterial Stiffness","Caucasian Whites","Inflammation","Microvascular Function",[79,80,71,64,81,82,83,84,85,86,87],"Blueberries","Hypertension","Endothelial Function","Cognitive Function","Dietary intervention","functional foods","gut microbiota","arterial stiffness","microvascular function","2026-03-23",{"date":90,"type":37},"2026-03-27",{"date":92,"type":37},"2024-09-17",{"date":94,"type":21},"2027-01-01",{"name":96,"class":97},"Georgia State University","OTHER",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":105,"maxAge":55,"enrollmentInfo":106,"targetDuration":4,"studyType":58,"phases":108,"briefSummary":109,"conditions":110,"keywords":114,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":45},"100572621","wild-blueberries-for-gut-brain-and-cardiometabolic-health-in-prediabetes-100572621","NCT06735651","Wild Blueberries for Gut, Brain, and Cardiometabolic Health in Prediabetes","Wild Blueberries for Gut, Brain, and Cardiometabolic Health in Female Adults With Prediabetes.","Inclusion Criteria:\n\n* Women aged 20-65 years old\n* Prediabetes (fasting blood glucose 100-125 mg\u002FdL and\u002For HbA1c percentage between 5.7-6.4)\n* Body Mass Index between 25-30 kg\u002Fm\\^2\n\nExclusion Criteria:\n\n* Allergies to berries\n* Use of insulin, antidiabetic, antibiotics, and anti-inflammatory drugs\n* Active cancer, gastrointestinal, renal, thyroid, stage 1 \\& 2 hypertension and other cardiovascular diseases, neurological diseases, or severe head injury\n* Smoking\n* Consumes greater than 2 alcoholic beverages per day\n* Consumes antioxidant, probiotic, and prebiotic supplements\n* Pregnant or Lactating\n* Actively participating in a weight loss program\n* Currently taking berry supplements or recently participated in another study taking berry supplements","20 Years",{"count":107,"type":21},30,[60],"The goal of this clinical trial is to determine the effectiveness of using a freeze-dried wild blueberry powder on cardiometabolic health, cognitive function, and gut microbiota composition in adult women with prediabetes.",[111,27,66,68,74,67,69,112,71,76,77,113],"Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)","Gut Microbiota","Body Composition",[79,115,116,117,83,118,119,120,121,122,123,124,77,125],"Prediabetes","Insulin Resistance","Functional foods","Endothelial function","Vascular function","Cardiovascular health","Metabolic health","Gut microbiota","Cognitive function","Type II diabetes","Wild Blueberries",{"date":127,"type":37},"2026-03-25",{"date":129,"type":37},"2024-09-20",{"date":131,"type":21},"2026-06-01",{"name":96,"class":97},{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":140,"sex":16,"minAge":141,"maxAge":54,"enrollmentInfo":142,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":153,"locationsCount":45},"100594971","physiological-and-psychological-profiles-100594971","NCT07026383","Physiological and Psychological Profiles","Physiological and Psychological Profiles of the Athletic Women and the Risk of Sport Injuries in Saudi Arabia","Inclusion Criteria:\n\n* Female athletes aged 18-35 years recruited from rugby and basketball teams in Saudi Arabia\n* Actively involved in rugby and basketball\n* Minimum of one year of experience in their respective sport\n* Regular participation in training and competitive events\n\nExclusion Criteria:\n\n* Recent injury within the last six months that limits athletic performance Pregnancy\n* Presence of any chronic medical condition that could influence study outcomes\n* Uncontrolled diabetes or hypertension",true,"18 Years",{"count":143,"type":21},60,"The participation of women in high-impact sports such as rugby and basketball has been steadily increasing in Saudi Arabia. These sports are known for their physical demands and competitive nature, which have heightened the incidence of sports-related injuries. Understanding the predictive factors for these injuries is critical for developing preventive strategies, reducing long-term health consequences, and reducing healthcare burdens. Therefore, this study aims to identify the predictive effect of physiological factors (e.g., muscle strength, anaerobic power, oxygen consumption) and psychological factors (e.g., self-efficacy, resilience) on sports injuries among female athletes in Saudi Arabia, particularly focusing on those involved in rugby and basketball.\n\nA prospective cross-sectional design will be employed, involving a total of 30 female athletes aged 18-35 years actively participating in rugby and basketball. Data will be collected at the lifestyle research center through a series of physiological assessments, including maximal oxygen consumption, anaerobic power testing, isokinetic muscle strength testing, and psychological evaluations using validated questionnaires. The findings are expected to provide insights into the specific factors that increase injury risk among Saudi female athletes, offering targeted strategies for injury prevention. These strategies aim not only to minimize injuries but also to reduce associated healthcare costs, thereby supporting the sustainable growth of women's sports in Saudi Arabia. Ultimately, this study seeks to contribute to the broader objectives of Vision 2030 by promoting a vibrant sports culture and enhancing public health.",[146,27],"Healthy Volunteer","2026-03-20",{"date":149,"type":37},"2026-03-24",{"date":151,"type":37},"2025-01-25",{"date":147,"type":21},{"name":154,"class":97},"Princess Nourah Bint Abdulrahman University",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":140,"sex":16,"minAge":105,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":45},"100624912","a-quantitative-cross-sectional-and-observational-study-to-characterize-age-related-structural-changes-in-facial-skin-of-chinese-women-using-line-field-confocal-optical-coherence-tomography-lc-oct-100624912","NCT07415798","A Quantitative, Cross-Sectional and Observational Study to Characterize Age-Related Structural Changes in Facial Skin of Chinese Women Using Line-Field Confocal Optical Coherence Tomography (LC-OCT)","Inclusion Criteria:\n\n1. Chinese female, aged between 20 and 70 years (inclusive) at the time of signing consent.\n2. Willing and able to provide written informed consent.\n3. Fitzpatrick Skin Phototype II or III.\n4. Willing to comply with all study procedures, including removal of facial makeup and avoidance of intensive skincare (e.g., retinoids, strong acids) on the test areas for 3 days prior to the visit as per instructions.\n\nExclusion Criteria:\n\n1. Pregnant, planning pregnancy, or breastfeeding (as hormonal changes significantly affect skin properties).\n2. Presence of temporary tanning, sunburn, or significant erythema on the face or measurement areas.\n3. Presence of facial piercings, tattoos, too much fluff or significant scarring that would interfere with imaging or measurements in the areas of interest.\n4. History of any aesthetic or surgical procedure on the face (e.g., laser therapy, chemical peels, injectable fillers, botulinum toxin, plastic surgery) within the past 12 months.\n5. Current diagnosis or visible signs of a skin disease (e.g., psoriasis, eczema, active acne, rosacea) or a systemic disease known to affect the skin (e.g., diabetes, lupus) on the face or measurement areas.\n6. Use of systemic medications known to affect skin physiology (e.g., oral retinoids, immunosuppressants, long-term corticosteroids) within the past 3 months, or for a cumulative duration of ≥6 months within the past 2 years.\n7. Participation in another clinical study on the face or arms within the past 1 month.","70 Years",{"count":163,"type":21},100,"This is a single-center, non-interventional, observational, cross-sectional clinical study designed to quantitatively and qualitatively characterize skin properties in a cohort of 100 Chinese female Subjects aged 20 to 70 years. The study involves no product application and poses minimal risk to participants. The primary objectives are to establish a comprehensive skin aging profile database, characterize skin color, aging signs, and biomechanical properties, and create a histomorphometric database for the development and validation of ordinal photographic scales for aging research. Data will be collected through questionnaires, clinical assessments (including LC-OCT imaging), standardized photography, and non-invasive biophysical measurements. All procedures will be conducted in accordance with the ethical principles originating from the Declaration of Helsinki, the International Council for Harmonisation Good Clinical Practice (ICH-GCP) guidelines, and the relevant laws and regulations of China (including the \\*Measures for the Ethical Review of Biomedical Research Involving Human Subjects\\*). All data will be anonymized and stored securely.",[27,166],"Facial Skin","2026-02-10",{"date":169,"type":37},"2026-02-17",{"date":171,"type":37},"2026-01-15",{"date":173,"type":21},"2027-01-15",{"name":175,"class":176},"ChinaNorm","INDUSTRY",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":16,"minAge":105,"maxAge":161,"enrollmentInfo":184,"targetDuration":4,"studyType":58,"phases":186,"briefSummary":188,"conditions":189,"keywords":190,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":45},"100618786","phase-2-dostarlimab-cisplatin-and-etoposide-in-combination-with-radiotherapy-in-sandwich-sequence-for-small-cell-neuroendocrine-cervical-carcinoma-100618786","NCT07336147","Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical Carcinoma","Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical Carcinoma (DICER Trial): Taiwanese Gynecologic Oncology Group (TGOG) 1012","Inclusion Criteria:\n\n1. Female participants who are 20-70 years of age on the day of signing informed consent with histologically confirmed diagnosis of Previously untreated SCNECC IB2-IV or IB1 with LVSI or IVB with oligometastasis (only in one distant organ not more than 2 nodules which can be encompassed by RT) will be enrolled in this study.\n\n   \\*A female participant is eligible to participate if she is not pregnant (see Appendix 3), not breastfeeding, and at least one of the following conditions applies:\n   1. Not a woman of childbearing potential (WOCBP) as defined in Appendix 3 OR\n   2. A WOCBP who agrees to participate this trial should be informed that after the protocol treatment the ovarian function and child-bearing potential will be permanently lost and she has to follow the contraceptive guidance in Appendix 3 after enrollment through neoadjuvant chemoimmuntherapy period till external beam radiotherapy (EBRT) commences.\n2. Have provided archival tumor tissue sample or newly obtained biopsy of a tumor lesion not previously irradiated. Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides. Newly obtained biopsies are preferred to archival tissue. At least 5 punch biopsiesdof 3mm in diameter.\n3. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. Evaluation of ECOG is to be performed within 7 days prior to the first dose of study intervention.\n\nExclusion Criteria:\n\n1. A WOCBP who has a positive urine pregnancy test within 72 hours prior to allocation. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n\n   Note: in the event that 72 hours have elapsed between the screening pregnancy test and the first dose of study treatment, another pregnancy test (urine or serum) must be performed and must be negative in order for subject to start receiving study medication.\n2. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137).\n3. Has received prior systemic anti-cancer therapy for SCNECC including investigational agents prior to enrollment.\n4. Has received prior pelvic radiotherapy.\n5. Has received radical surgery for cervical cancer.\n6. Has received a live vaccine or live-attenuated vaccine within 30 days prior to the first dose of study drug. Administration of killed vaccines is allowed.\n7. Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention.\n8. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.\n9. Has a known additional malignancy that is progressing or has required active treatment within the past 3 years. Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.\n10. Has known active CNS metastases and\u002For carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study intervention.\n11. Has severe hypersensitivity (≥Grade 3) to dostarlimab and\u002For any of its excipients.\n12. Participant has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment.\n13. Has a history of (non-infectious) pneumonitis\u002Finterstitial lung disease that required steroids or has current pneumonitis\u002Finterstitial lung disease.\n14. Has an active infection requiring systemic therapy.\n15. Has a known history of Human Immunodeficiency Virus (HIV) infection. Note: No HIV testing is required unless mandated by local health authority.\n16. Has a known history of untreated Hepatitis B (defined as Hepatitis B surface antigen \\[HBsAg\\] reactive) or known active Hepatitis C virus infection (for those with anti-HCV+, patients who ever HCV RNA positive should undergo 8-12 weeks direct acting agents (DAA) treatment and confirmed with HCV cure, defined as HCV RNA negative at week 12 post end-of-treatment). Note: Testing for Hepatitis B and Hepatitis C is required but the patient is eligible if well controlled.\n17. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.\n18. Allergy: Participant cannot have history of severe allergic and\u002For anaphylactic reactions to chimeric, human or humanized antibodies or fusion proteins, sensitivity to any of the study treatments or components thereof, or a history of drug or other allergy that contraindicates their participation.\n19. Has had an allogenic tissue\u002Fsolid organ transplant.\n20. Participant has received a live vaccine within 30 days of planned start of study therapy. COVID-19 vaccines that do not contain live viruses are allowed. Note: mRNA and adenoviral-based COVID-19 vaccines are considered non-live.\n21. Participant has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal\u002Fgastric varices, or persistent jaundice.\n\nNote: Stable non-cirrhotic chronic liver disease (including Gilbert's syndrome or asymptomatic gallstones) is acceptable if participant otherwise meets entry criteria.\n\n\\-",{"count":185,"type":21},45,[187],"PHASE2","Add-on dostarlimab to chemoradiation with etoposide and cisplatin and radiotherapy can improve progression-free survival (PFS) compared with historical controls who were treated with chemoradiation alone in SCNECC",[27],[191,192,193,194],"dostarlimab","cisplatin","etoposide","cervical carcinoma","2026-01-12",{"date":197,"type":37},"2026-01-14",{"date":199,"type":37},"2025-12-22",{"date":201,"type":21},"2030-12-22",{"name":203,"class":97},"Chang Gung Memorial Hospital",{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":16,"minAge":105,"maxAge":55,"enrollmentInfo":211,"targetDuration":4,"studyType":58,"phases":212,"briefSummary":213,"conditions":214,"keywords":216,"overallStatus":226,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":231,"leadSponsor":233,"locationsCount":4},"100618211","pain-neuroscience-education-and-basic-body-awareness-therapy-in-women-with-chronic-pelvic-pain-100618211","NCT07328672","Pain Neuroscience Education and Basic Body Awareness Therapy in Women With Chronic Pelvic Pain","Investigation of the Effects of Pain Neuroscience Education and Basic Body Awareness Therapy on Pain, Autonomic Nervous System Responses, and Pelvic Floor Muscle Activity in Women With Chronic Pelvic Pain","Inclusion Criteria:\n\n* Women with any type of chronic pelvic pain, including pelvic floor muscle dysfunction, endometriosis, vulvodynia, genito-pelvic pain\u002Fpenetration disorder, or bladder pain syndrome, with pain persisting for six months or longer.\n\nExclusion Criteria:\n\n* Presence of pelvic infections, inflammatory conditions, or pelvic malignancy.\n* Pregnancy.\n* History of urogynecological surgery within the last six months.\n* Presence of advanced pelvic organ prolapse.\n* Patients currently receiving chemotherapy or radiotherapy.\n* Patients whose primary complaint is not chronic pelvic pain.",{"count":185,"type":21},[60],"This randomized controlled trial aims to investigate the effects of Pain Neuroscience Education and Basic Body Awareness Therapy, when added to standard physiotherapy and rehabilitation, on pain, autonomic nervous system responses, and pelvic floor muscle activity in women with chronic pelvic pain. A total of 45 women diagnosed with chronic pelvic pain will be randomly allocated into three groups: (1) standard physiotherapy and rehabilitation, (2) standard physiotherapy plus Pain Neuroscience Education, and (3) standard physiotherapy plus Basic Body Awareness Therapy. The study will assess pain intensity (algometry, NRS, SF-MPQ), pain catastrophizing, autonomic responses (electrodermal activity), pelvic floor muscle activation (EMG), and related psychological, cognitive, and body awareness parameters. Secondary outcomes will include sexual function, quality of life, and patient satisfaction. The aim is to compare two awareness-based interventions-one primarily mind-to-body (Pain Neuroscience Education) and the other body-to-mind (Basic Body Awareness Therapy)-to determine their relative and complementary effects on pain perception and physiological regulation in women with chronic pelvic pain.",[215,27],"Chronic Pelvic Pain Syndrome",[217,218,219,220,221,222,223,224,225],"Body Awareness","Basic Body Awareness Therapy","Pelvic Floor Muscle Activity","Autonomic Nervous System","Physiotherapy","Rehabilitation","Chronic Pelvic Pain","Pelvic Floor Muscles","Pain Neuroscience Education","NOT_YET_RECRUITING","2025-12-27",{"date":229,"type":37},"2026-01-09",{"date":171,"type":21},{"date":232,"type":21},"2026-12-15",{"name":234,"class":97},"Sena Öndeş",{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":16,"minAge":141,"maxAge":4,"enrollmentInfo":242,"targetDuration":4,"studyType":58,"phases":243,"briefSummary":244,"conditions":245,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":45},"100604772","oral-mucosal-graft-versus-labial-graft-in-female-urethroplasty-100604772","NCT07153861","Oral Mucosal Graft Versus Labial Graft in Female Urethroplasty","Oral Mucosal Graft Versus Labial Graft in Female Urethroplasty: A Prospective Comparative Study","Inclusion Criteria:\n\n* Female patients with urethral stricture.\n* Female patients with non-traumatic urethral stricture.\n\nExclusion Criteria:\n\n* Female patients with traumatic urethral stricture.\n* Female patients with systemic contraindications of surgery like bleeding disorders.",{"count":57,"type":21},[60],"This study aims to compare the oral versus labial graft in female urethroplasty in female urethral stricture.",[246,247,27,248],"Oral Mucosal Graft","Labial Graft","Urethroplasty","2025-08-30",{"date":251,"type":37},"2025-09-04",{"date":253,"type":37},"2025-02-26",{"date":255,"type":21},"2026-01-01",{"name":257,"class":97},"Tanta University",{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":140,"sex":16,"minAge":265,"maxAge":266,"enrollmentInfo":267,"targetDuration":269,"studyType":23,"phases":4,"briefSummary":270,"conditions":271,"keywords":275,"overallStatus":226,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":4},"100587170","exploring-pelvic-floor-dysfunction-among-egyptian-female-athletes-100587170","NCT06924905","Exploring Pelvic Floor Dysfunction Among Egyptian Female Athletes","Exploring Pelvic Floor Dysfunction Among Egyptian Female Athletes: Prevalence, Risk Factors, and Implications for Performance","Inclusion Criteria:\n\n* Their age will range from 16 to 60 years.\n* Female gender only.\n* Females engaged in regular sports or athletic activities..\n* Currently residing in Egypt\n\nExclusion Criteria:\n\n* Not currently involved in sports or physical activities.\n* Egyptian females living outside Egypt.\n* Participants involved in para-athletics.","16 Years","60 Years",{"count":268,"type":21},50,"1 Month","This Study is aiming to identify the prevalence of pelvic floor dysfunction in female athletes in Egypt and which sports contribute more in increasing their number. helping in gathering information about the risk factors and raising awarness about Pelvic floor dysfunction",[272,273,27,274],"Sports","Public Health","Pelvic Diseases",[273,276,277],"Pelvic Disorders","pelvic dysfunctions","2025-04-05",{"date":280,"type":37},"2025-04-13",{"date":282,"type":21},"2025-04",{"date":284,"type":21},"2025-10",{"name":286,"class":97},"Cairo University",{"id":288,"slug":289,"hasResults":11,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":293,"eligibilityCriteria":294,"healthyVolunteers":140,"sex":16,"minAge":141,"maxAge":295,"enrollmentInfo":296,"targetDuration":298,"studyType":23,"phases":4,"briefSummary":299,"conditions":300,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":317},"100564215","fertility-and-ovarian-reserve-in-female-childhood-cancer-survivors-100564215","NCT06626282","Fertility and Ovarian Reserve in Female Childhood Cancer Survivors","PReserving Fertility and Quality of Life IN Belgian Female Paediatric CancEr SurvivorS","PRINCESS","Inclusion Criteria:\n\n* Child and adolescent female patients included in the Paediatrics Late Effects Project:\n* diagnosed with cancer1 between 01\u002F01\u002F2004 and 31\u002F12\u002F2018\n* \\\u003C17 years old at diagnosis\n* treated at CHU Liège site Citadelle or CHC, Cliniques Universitaires Saint-Luc and HUDERF\n* alive\n* ≥ 18 years-old at time of recruitment.\n\nExclusion Criteria:\n\n* Cancer diagnosis for controls","50 Years",{"count":297,"type":21},340,"3 Months","Ovarian function impairment affects the quality of life of the survivors of paediatric cancer by impacting fertility, bone quality and mental and cognitive health. The objective of this project is to evaluate the impact of low-intermediate dose alkylating agents associated or not with ovarian cryopreservation technique on ovarian function in female survivors of paediatric cancer. We propose to identify new epigenetic markers in order to predict the risk of premature ovarian insufficiency. The project will be led by a national multi-disciplinary team (paediatric oncologists, gynaecologists, endocrinologists). Paediatric cancer clinical data (therapy, fertility preservation, ...) will be extracted from the Paediatrics Late Effects database and additional data will be collected during PRINCESS fertility evaluation. Through translational and multi-disciplinary approaches, results should improve quality of life and fertility preservation in female survivors of paediatric cancer by developing new personalised screening tools for premature ovarian insufficiency.",[301,302,303,304,305,306,307,27],"Childhood Cancer Survivors","Fertility","Ovarian Reserve","CED","Ovarian Reserve Markers","Cryopreservation","Alkylating Agents","2024-10-30",{"date":310,"type":37},"2024-11-01",{"date":312,"type":37},"2024-10-09",{"date":314,"type":21},"2028-12-31",{"name":316,"class":97},"Centre Hospitalier Universitaire de Liege",3,{"id":319,"slug":320,"hasResults":11,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":324,"eligibilityCriteria":325,"healthyVolunteers":11,"sex":53,"minAge":141,"maxAge":4,"enrollmentInfo":326,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":328,"conditions":329,"keywords":331,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":45},"100558730","sex-specific-differences-in-cardiac-surgery-patients-secs-100558730","NCT06554925","SEx-specific Differences in Cardiac Surgery Patients (SECS).","SEx-specific Differences in Cardiac Surgery Patients (SECS). A Retrospective Registration and Evaluation of Characteristics and Perioperative Management of Cardiac Surgery Patients","SECS","Inclusion Criteria:\n\n* Patients \\> 18 years\n* All patients who underwent cardiac surgery from 1 January 1998 in the AUMC, location VUmc, until 1 June 2021.\n\nExclusion Criteria:\n\n* None",{"count":327,"type":21},10000,"The aim of this study is to evaluate the differences between females and males undergoing cardiac surgery. The investigators will look at perioperative factors such as adaption of body weight, previous medical history, pharmacokinetics, transfusion, coagulation, cardiopulmonary bypass (CPB) related factors, cardiac function, inotropic requirements, risk, and outcome scores as well as morbidity and mortality at sort-term (within 30 days) and long-term (90 days and 1 year).",[27,65,330],"Surgery, Cardiac",[332,333,334,335],"anesthesia","sex-specific differences","cardiac surgery","care pathways","2024-08-12",{"date":338,"type":37},"2024-08-15",{"date":340,"type":37},"2022-03-01",{"date":342,"type":21},"2031-03-01",{"name":344,"class":97},"Jennifer Breel",{"id":346,"slug":347,"hasResults":11,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":4,"eligibilityCriteria":351,"healthyVolunteers":11,"sex":16,"minAge":265,"maxAge":352,"enrollmentInfo":353,"targetDuration":355,"studyType":23,"phases":4,"briefSummary":356,"conditions":357,"keywords":362,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":45},"100543111","epidemiology-of-injuries-in-the-professional-womens-swedish-national-icehockey-league-permitted-to-body-checking-100543111","NCT06351618","Epidemiology of Injuries in the Professional Women's Swedish National IceHockey League Permitted to Body-Checking","Swedish Female Ice Hockey Injury Study","Inclusion Criteria:\n\n* minimum 16 years of age, registered player in the highest Swedish professional ice hockey league for women, SDHL\n\nExclusion Criteria:\n\n* age under 16 years.","110 Years",{"count":354,"type":21},225,"5 Years","This research project can contribute to a deeper understanding of injury patterns among professional female ice-hockey players allowed to body check. An understanding of common injury types and mechanisms aids the clinician in diagnosis and management. This information can guide preventative strategies in the areas of education, coaching, rule enforcement, rule modifications, equipment improvement, and sportsmanship. Today, ice hockey is a sport associated with many severe injuries that not only causes suffering and lower quality of life for the athlete, but also costs society a lot of money. Reducing the number and severity of sport-related injuries is therefore of importance. Knowledge of the injury epidemiology of women's hockey could also contribute to better preventive training programs and other injury preventive actions in the sport. Currently, only a minority of all sports medicine research is made on female study participants (26). This research project has the possibility to gain more knowledge about the female athlete, not only applicable for elite hockey-players, but also for female athletes in different disciplines and in youth teams. Knowledge of factors associated with injury could also contribute to better injury preventive actions and highlight subgroups in extra need of future preventive interventions.",[358,359,360,361,27],"Sport Injury","Ice-Skates Accident","Sports Accident","Female Athlete Triad",[363,364,365,366,367],"women's health","Ice hockey","Elite sport","Injuries","Bodychecking","2024-04-02",{"date":370,"type":37},"2024-04-08",{"date":372,"type":37},"2023-12-01",{"date":374,"type":21},"2028-01-01",{"name":376,"class":97},"Lund University",{"id":378,"slug":379,"hasResults":11,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":383,"eligibilityCriteria":384,"healthyVolunteers":11,"sex":53,"minAge":141,"maxAge":4,"enrollmentInfo":385,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":387,"conditions":388,"keywords":390,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":45},"100529582","towards-a-sex-specific-female-enhanced-recovery-after-cardiac-surgery-f-eras-pathway-100529582","NCT06175650","Towards a Sex-specific \"Female Enhanced Recovery After Cardiac Surgery'' (F-ERAS) Pathway:","Towards a Sex-specific \"Female Enhanced Recovery After Cardiac Surgery'' (F-ERAS) Pathway: An Observational Registration and Evaluation of Characteristics and Perioperative Management of Cardiac Surgery Patients","F-ERAS","Inclusion Criteria:\n\n* Patients \\> 18 years\n* All patients who underwent cardiac surgery from 1 January 2016 to the start of the study, in either of the centres (AMC or VUmc) (retrospective)\n* All patients undergoing cardiac surgery from the start of the study (\\~March 2022) until approximately 2032\n\nExclusion Criteria:\n\n• Patients who object to the re-use of their care data or do not give consent",{"count":386,"type":21},5500,"The aim of this study is to evaluate the differences between men and women undergoing cardiac surgery. We will look at perioperative factors such as body weight, body surface area, previous medical history, pharmacokinetics, transfusion, coagulation, cardiopulmonary bypass (CPB) related factors, cardiac function, inotropic requirements, risk, and outcome scores as well as morbidity and mortality at 30 and 90 days, 1, 5, and 10 years.",[27,65,389],"Surgery,Cardiac",[391,392],"Anesthesia","Quality of Life","2023-12-18",{"date":395,"type":37},"2023-12-19",{"date":397,"type":37},"2023-11-21",{"date":399,"type":21},"2026-11-21",{"name":344,"class":97},{"id":402,"slug":403,"hasResults":11,"nctId":404,"briefTitle":405,"officialTitle":406,"acronym":4,"eligibilityCriteria":407,"healthyVolunteers":11,"sex":53,"minAge":141,"maxAge":266,"enrollmentInfo":408,"targetDuration":4,"studyType":58,"phases":410,"briefSummary":411,"conditions":412,"keywords":419,"overallStatus":226,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":432,"locationsCount":4},"100471348","efficacy-of-transcutaneous-vagus-nerve-stimulation-paired-with-tailor-made-notched-music-therapy-versus-tailor-made-notched-music-training-for-chronic-subjective-tinnitus-100471348","NCT05417711","Efficacy of Transcutaneous Vagus Nerve Stimulation Paired With Tailor-Made Notched Music Therapy Versus Tailor-made Notched Music Training for Chronic Subjective Tinnitus","Efficacy of Transcutaneous Vagus Nerve Stimulation Paired With Tailor-Made Notched Music Therapy Versus Tailor-made Notched Music Training for Chronic Subjective Tinnitus: A Multicenter, Randomized, Double-blind, Controlled Clinical Trial","Inclusion Criteria:\n\n* Patients with tinnitus as the main complaint: the patients subjectively feel the sound in the ear or deep part of the head without internal or external sound stimulation, and therefore seek medical treatment\n* Chronic (≥ 6 months) and tonal tinnitus\n* Age 18-60\n* Tinnitus frequency is 125-8000 Hz\n* Hearing threshold at each frequency shall not exceed 70 dB HL\n\nExclusion Criteria:\n\n* Patients with conductive deafness, history of middle ear surgery, pulsatile tinnitus caused by vascular distortion and tinnitus caused by Meniere disease\n* History of head trauma, central nervous system diseases, mental diseases and drug abuse",{"count":409,"type":21},388,[60],"This clinical study is a prospective, multicenter, randomized, controlled, double-blind clinical study. Sun Yat Sen Memorial Hospital of Sun Yat sen University was the central unit, and Nanjing First Hospital, Sun Yat Sen people's Hospital, Guanfzhou Panyu central Hospital and Zhuhai integrated traditional Chinese and Western medicine hospital were the cooperative units. In this study, 388 patients with chronic subjective tinnitus were recruited. In view of chronic subjective tinnitus, a common ear disease, the study gave the patients three months of treatment with transcutaneous vagus nerve stimulation paired with tailor-made notched music therapy or tailor-made notched music training alone. By comparing the changes of subjective scale scores related to tinnitus before and after treatment in patients receiving two different therapies, such as THI, VAS, BAI, BDI, PSQI, to evaluate the efficacy of the two therapies, so as to judge whether transcutaneous vagus nerve stimulation paired with tailor-made notched music therapy is better than tailor-made notched music training alone. In addition, the study will continue to follow up the patients after the treatment for one year to observe the difference in the long-term sustained efficacy of the two therapies. This clinical study will also evaluate the two therapies from the perspective of compliance and safety, and explore the factors that affect the efficacy of the two therapies.",[413,414,415,416,27,65,417,418],"Tinnitus, Subjective","Vagus Nerve Stimulation","Music Therapy","Double-Blind Method","Humans","Treatment Outcome",[420,421,422,423,424],"Chronic subjective tinnitus","Tailor-made notched music training","Vagus nerve stimulation","Electroencephalogram","Clinical trial","2023-11-22",{"date":427,"type":37},"2023-11-27",{"date":429,"type":21},"2023-11-23",{"date":431,"type":21},"2026-09-01",{"name":433,"class":97},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University"]